| Trade Names: | |
| Synonyms: | |
| Status: | Approved (1960) |
| Entry Type: | Small molecule |
| Molecule Category: | Parent |
| ATC: | C02AA02 |
| UNII: | 8B1QWR724A |
| InChI Key | QEVHRUUCFGRFIF-MDEJGZGSSA-N |
|---|---|
| Smile | |
| InChI |
|
| Property Name | Value |
|---|---|
| Molecular Formula | C33H40N2O9 |
| Molecular Weight | 608.69 |
| AlogP | 4.17 |
| Hydrogen Bond Acceptor | 10.0 |
| Hydrogen Bond Donor | 1.0 |
| Number of Rotational Bond | 8.0 |
| Polar Surface Area | 117.78 |
| Molecular species | NEUTRAL |
| Aromatic Rings | 3.0 |
| Heavy Atoms | 44.0 |
| Action | Mechanism of Action | Reference |
|---|---|---|
| INHIBITOR | Synaptic vesicular amine transporter inhibitor |
| Primary Target | |
|---|---|
| Vesicular monoamine transporter 2 |
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Hypercholesterolemia | 3 | D006937 | ClinicalTrials |
| Heart Diseases | 3 | D006331 | ClinicalTrials |
| Atherosclerosis | 3 | D050197 | ClinicalTrials |
| Coronary Disease | 3 | D003327 | ClinicalTrials |
| Diabetes Mellitus, Type 2 | 3 | D003924 | ClinicalTrials |
| Cardiovascular Diseases | 3 | D002318 | ClinicalTrials |
| Cerebrovascular Disorders | 3 | D002561 | ClinicalTrials |
| Cocaine-Related Disorders | 2 | D019970 | ClinicalTrials |
| Vascular Diseases | 2 | D014652 | ClinicalTrials |
| Substance-Related Disorders | 2 | D019966 | ClinicalTrials |
| Amphetamine-Related Disorders | 1 | D019969 | ClinicalTrials |
| Hypertension, Pulmonary | 1 | D006976 | ClinicalTrials |
| Resources | Reference |
|---|---|
| CAS NUMBER | 50-55-5 |
| ChEBI | 28487 |
| ChEMBL | CHEMBL772 |
| DrugBank | DB00206 |
| DrugCentral | 2370 |
| EPA CompTox | DTXSID7021237 |
| FDA SRS | 8B1QWR724A |
| Human Metabolome Database | HMDB14351 |
| Guide to Pharmacology | 4823 |
| KEGG | C06539 |
| PDB | YHR |
| PharmGKB | PA451236 |
| PubChem | 5770 |
| SureChEMBL | SCHEMBL2589 |
| ZINC | ZINC000003938746 |